Head-to-head evidence
BCMA CAR-NK (Shenzhen Pregene Biopharma) vs Ciltacabtagene autoleucel
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Myeloma
Shared mechanism: BCMA · full Multiple Myeloma pipeline
BCMA CAR-NK (Shenzhen Pregene Biopharma)
Developed by Shenzhen Pregene Biopharma Co., Ltd.
NCT05652530 · Phase 1 · status unknown
This was an open-label, single-arm study with no randomization, no blinding, and no comparator arm, in only 19 participants, and it measured only safety. Results have not been posted yet.
Ciltacabtagene autoleucel
Marketed by Johnson & Johnson and partners
NCT03548207 · Phase 1/2 · completed
This was an open-label, single-group study with no randomized comparator and no blinding. Although the overall response rate among treated participants was high (e.g., 97.1% in the Phase 2 US population with 95% CI 89.8-99.6), the lack of a control arm means the results cannot be attributed to the drug with confidence. Uncontrolled single-arm evidence is inherently limited regardless of the response rate observed.
Next expected readout: February 2027 · NCT04133636 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: BCMA CAR-NK (Shenzhen Pregene Biopharma)'s landscape · Ciltacabtagene autoleucel's landscape